"As a long-term investor, with holding periods of over 10 years, Rangatira is an attractive investor partner to businesses and owners with a long-term view."
The firm reported a net profit of $6.6m in the 12 months ended March, down from $11.1m a year earlier. Operating earnings were $9.1m, down from $11.3m. Rangatira restated its earlier figures due to a change in how gains and losses were recorded.
The decline in operating earnings was due to a 10-month contribution from Hellers before it was sold and weaker performances from its stakes in Bio-Strategy, Rainbow's End, and Mrs Higgins.
Magritek outperformed the year-earlier performance and Rangatira has since lifted its stake to 25 per cent from 18 per cent. It has also invested in a gold kiwifruit development.
The company's shares trade on the Unlisted exchange. A-class and B-class Rangatira shares both last traded at $12.50. A-class shares carry full voting rights, while B-class shares are restricted to voting only on matters affecting their rights.